Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc V.VIV.H

Alternate Symbol(s):  VIVXF

Healthcare
Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


TSXV:VIV.H - Post by User

Avivagen Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by sandymackayon Feb 10, 2012 12:34pm
112 Views
Post# 19516390

CFR-corporate update

CFR-corporate update

Just read the corporate update and like the direction CFR is going.  With their proven, patent-backed Oxc-Beta, their  strategy is to monetize the technology using various avenues, including the expansion of their Oximunol supplement.

 

I like the fact that CFR plans to develop several new product lines using Oxc-beta...I think they could secure a deal with say a Pet Smart and get Oxc-Beta added as a supplement to pet food for dogs and cats. It would be a great marketing strategy for any pet food company to be able to advertise that they hold the exclusive rights to Oxc-beta, which has proven to increase immune function, coat quality and increased mobility and energy in pets!!!!

 

Sandy

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities